The Biomedical Research Institute (BRI)
The Biomedical Research Institute (BRI), is a 501 c-3 non-profit research company committed to improving global health through a variety of research and service activities. For over 40 years, with the financial support of the NIH, our mission has been to reduce the global health burden imposed by infectious diseases of the developing world in general, and targeting schistosomiasis in particular.
Towards these ends the NIH has supported an SR3 facility through which investigators can obtain schistosome life stages for research or teaching purposes, free of charge. The SR3 is housed at BRI under an NIH-NIAID contract entitled “Maintenance, Development and Production of Schistosomiasis Parasites, Reagents, and Assays”. Through this contract, the three major schistosome species affecting humans (Schistosoma mansoni, S. haematobium, and S. japonicum) can be obtained either in their specific snail host or in infected mammals. In addition, the SR3 is responsible for developing molecular reagents for schistosomiasis research that are made available to the research community. This service offers nucleic acids and other reagents derived from snails and parasites. Personnel associated with this project are also available to provide training and technical assistance to other laboratories on snail cultivation, parasite collection and host infection. The contract also allows us to provide molecular and life cycle training courses.
For more information, visit www.afbr-bri.com